title: Long-term interleukin-1alpha treatment inhibits insulin signaling via IL-6 production and SOCS3 expression in 3T3-L1 adipocytes.
abstract: Proinflammatory cytokines are well-known to inhibit insulin signaling to result in insulin resistance. IL-1alpha is also one of the proinflammatory cytokines, but the mechanism of how IL-1alpha induces insulin resistance remains unclear. We have now examined the effects of IL-1alpha on insulin signaling in 3T3-L1 adipocytes. Prolonged IL-1alpha treatment for 12 to 24 hours partially decreased the protein levels as well as the insulin-stimulated tyrosine phosphorylation of IRS-1 and Akt phosphorylation. mRNA for SOCS3, an endogenous inhibitor of insulin signaling, was dramatically augmented 4 hours after IL-1alpha treatment. Concomitantly, the level of IL-6 in the medium and STAT3 phosphorylation were increased by the prolonged IL-1alpha treatment. Addition of anti-IL-6 neutralizing antibody to the medium or overexpression of dominant-negative STAT3 decreased the IL-1alpha-stimulated STAT3 activation and SOCS3 induction, and ameliorated insulin signaling. These results suggest that the IL-1alpha-mediated deterioration of insulin signaling is largely due to the IL-6 production and SOCS3 induction in 3T3-L1 adipocytes.
authors: First Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan.
authors: T
authors: T
authors: Uno
authors: J
authors: J
authors: He
authors: I
authors: I
authors: Usui
authors: Y
authors: Y
authors: Kanatani
authors: A
authors: A
authors: Bukhari
authors: S
authors: S
authors: Fujisaka
authors: Y
authors: Y
authors: Yamazaki
authors: H
authors: H
authors: Suzuki
authors: M
authors: M
authors: Iwata
authors: M
authors: M
authors: Ishiki
authors: M
authors: M
authors: Urakaze
authors: T
authors: T
authors: Haruta
authors: H
authors: H
authors: Ogawa
authors: M
authors: M
authors: Kobayashi
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D005799:Genes, Dominant; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D053582:Interleukin-1alpha / Q000494:pharmacology*; D015850:Interleukin-6 / Q000096:biosynthesis*; D051379:Mice; D009500:Neutralization Tests; D010766:Phosphorylation / Q000187:drug effects; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000906:Antibodies; D007328:Insulin; D053582:Interleukin-1alpha; D015850:Interleukin-6; D050796:STAT3 Transcription Factor; C491411:Socs3 protein, mouse; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins